118 related articles for article (PubMed ID: 7493678)
1. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation.
Acharya J; Westwood NB; Sawyer BM; Messinezy M; Burroughs AK; Mehta AB; Pearson TC
Eur J Haematol; 1995 Nov; 55(5):315-21. PubMed ID: 7493678
[TBL] [Abstract][Full Text] [Related]
2. Variable X-chromosome DNA methylation patterns detected with probe M27 beta in a series of lymphoid and myeloid malignancies.
Hodges E; Howell WM; Boyd Y; Smith JL
Br J Haematol; 1991 Mar; 77(3):315-22. PubMed ID: 2012755
[TBL] [Abstract][Full Text] [Related]
3. Clonal analysis of human tumors with M27 beta, a highly informative polymorphic X chromosomal probe.
Fey MF; Peter HJ; Hinds HL; Zimmermann A; Liechti-Gallati S; Gerber H; Studer H; Tobler A
J Clin Invest; 1992 May; 89(5):1438-44. PubMed ID: 1349026
[TBL] [Abstract][Full Text] [Related]
4. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.
Brière JB
Semin Thromb Hemost; 2006 Apr; 32(3):208-18. PubMed ID: 16673275
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
De Stefano V; Teofili L; Leone G; Michiels JJ
Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199
[TBL] [Abstract][Full Text] [Related]
6. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.
Valla D; Casadevall N; Lacombe C; Varet B; Goldwasser E; Franco D; Maillard JN; Pariente EA; Leporrier M; Rueff B
Ann Intern Med; 1985 Sep; 103(3):329-34. PubMed ID: 4026081
[TBL] [Abstract][Full Text] [Related]
7. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement.
Tsukamoto N; Morita K; Maehara T; Okamoto K; Sakai H; Karasawa M; Naruse T; Omine M
Br J Haematol; 1994 Feb; 86(2):253-8. PubMed ID: 7911034
[TBL] [Abstract][Full Text] [Related]
8. Assessment of X-chromosome inactivation patterns using the hypervariable probe M27 beta in normal hemopoietic cells and acute myeloid leukemic blasts.
Gale RE; Wheadon H; Linch DC
Leukemia; 1992 Jul; 6(7):649-55. PubMed ID: 1352560
[TBL] [Abstract][Full Text] [Related]
9. A clonal study of hematopoiesis using the M27 beta probe: aberrant band patterns caused by incomplete digestion of a methyl-sensitive enzyme in the the inactive X-chromosome.
Jinnai I; Yoshida S; Toyoda A; Murohashi I; Bessho M; Hirashima K; Nagai K; Tomonaga M; Boyd Y
Leukemia; 1993 Sep; 7(9):1432-6. PubMed ID: 8103812
[TBL] [Abstract][Full Text] [Related]
10. Methylation patterns at the hypervariable X-chromosome locus DXS255 (M27 beta): correlation with X-inactivation status.
Boyd Y; Fraser NJ
Genomics; 1990 Jun; 7(2):182-7. PubMed ID: 1693357
[TBL] [Abstract][Full Text] [Related]
11. Methylation of the DXS255 hypervariable locus 5' CCGG site may be affected by factors other than X-chromosome activation status.
Cachia PG; Culligan DJ; Thomas ED; Whittaker J; Jacobs A; Padua RA
Genomics; 1992 Sep; 14(1):70-4. PubMed ID: 1358800
[TBL] [Abstract][Full Text] [Related]
12. Wiskott-Aldrich syndrome carrier detection with the hypervariable marker M27 beta.
de Saint Basile G; Notarangelo LD; Bonaiti-Pellié C; Doussau M; Prolini O; Craig IW; Ugazio A; Griscelli C; Fischer A
Hum Genet; 1992 May; 89(2):223-8. PubMed ID: 1350264
[TBL] [Abstract][Full Text] [Related]
13. X chromosome inactivation in fibroblasts of mentally retarded female carriers of the fragile site Xq27.3: application of the probe M27 beta to evaluate X inactivation status.
Schmidt M; Du Sart D; Kalitsis P; Fraser N; Leversha M; Voullaire L; Foster D; Davies J; Hills L; Petrovic V
Am J Med Genet; 1991; 38(2-3):411-5. PubMed ID: 1673316
[TBL] [Abstract][Full Text] [Related]
14. Clonality markers in polycythaemia and primary thrombocythaemia.
Briere J; el-Kassar N
Baillieres Clin Haematol; 1998 Dec; 11(4):787-801. PubMed ID: 10640217
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
16. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state.
Pagliuca A; Mufti GJ; Janossa-Tahernia M; Eridani S; Westwood NB; Thumpston J; Sawyer B; Sturgess R; Williams R
Q J Med; 1990 Sep; 76(281):981-9. PubMed ID: 2236481
[TBL] [Abstract][Full Text] [Related]
17. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.
Yan L; Elkassar N; Gardin C; Briere J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():31-40. PubMed ID: 8951770
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; Thanigaikumar M; Yallop D; Arya R; Pagliuca A; Gäken J; Wendon J; Heaton ND; Mufti GJ
Gastroenterology; 2006 Jun; 130(7):2031-8. PubMed ID: 16762626
[TBL] [Abstract][Full Text] [Related]
19. The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease.
Lucas GS; Padua RA; Masters GS; Oscier DG; Jacobs A
Br J Haematol; 1989 Aug; 72(4):530-3. PubMed ID: 2775657
[TBL] [Abstract][Full Text] [Related]
20. Clonal haemopoiesis following cytotoxic therapy for lymphoma.
Cachia PG; Culligan DJ; Clark RE; Whittaker JA; Jacobs A; Padua RA
Leukemia; 1993 Jun; 7(6):795-800. PubMed ID: 8501974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
